Loading
John Barnett

John Barnett

President and Chief Sc Officer, ExesaLibero Pharma, Inc
United States
I have supervised a research laboratory for many years, and during my career, I have had >30 grants and have published extensively on the results obtained from these grants. Prior to extending my management commitment of ExesaLibero to full-time, I chaired a basic science department that has 22 primary faculty members. I have had ongoing collaborative studies with the other investigators on this project for several years. During these collaborative studies, we extended my previous work with N-methyl 3,4-dichloropropananilide to characterize the effect of this compound on osteoclast differentiation and inhibition of mouse arthritis models and multiple myeloma. We established its mode of action on TRPC calcium channels at pharmacologically effective concentrations and calcium-release activated calcium (CRAC) channels at super pharmacological doses. II have led the development as well as managing the day-to-day affairs of the small business entity.

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS